|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Thioctic Acid co-treated with Saxitoxin] affects the activity of ABCB1 protein |
CTD |
PMID:29128272 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of ACADL mRNA] |
CTD |
PMID:22464149 |
|
NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP ISO |
Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in increased expression of ACE] Thioctic Acid affects the reaction [Dietary Fats affects the activity of ACE protein]; Thioctic Acid affects the reaction [Dietary Fats affects the expression of ACE mRNA] |
CTD |
PMID:26518973 PMID:27260466 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP ISO |
[Thioctic Acid co-treated with Pilocarpine] results in increased activity of ACHE protein; Thioctic Acid inhibits the reaction [Pilocarpine results in decreased expression of ACHE protein] [Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of ACHE protein; Hexachlorocyclohexane inhibits the reaction [[Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of ACHE protein] |
CTD |
PMID:19669875 PMID:20663516 PMID:20730314 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:22464149 |
|
NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Mitogens results in increased expression of ACTA2 protein]; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of ACTA2 mRNA]; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein] |
CTD |
PMID:21251946 PMID:24704557 PMID:29760339 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Valproic Acid] results in decreased activity of ADA protein |
CTD |
PMID:32662911 |
|
NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ mRNA]; Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] Thioctic Acid results in increased expression of ADIPOQ mRNA; Thioctic Acid results in increased expression of ADIPOQ protein |
CTD |
PMID:22664981 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[Thioctic Acid co-treated with Dietary Fats] results in decreased expression of AGT mRNA |
CTD |
PMID:27260466 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP ISO |
Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in increased expression of AGTR1] Thioctic Acid affects the reaction [Dietary Fats affects the expression of AGTR1A mRNA] |
CTD |
PMID:26518973 PMID:27260466 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Thioctic Acid results in decreased phosphorylation of AKT1 protein Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of AKT1 mRNA] |
CTD |
PMID:21351249 PMID:27260466 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [gallium arsenide results in decreased activity of ALAD protein]; Thioctic Acid inhibits the reaction [Pilocarpine results in decreased expression of ALAD protein] |
CTD |
PMID:19798568 PMID:20026167 PMID:20584200 PMID:21783994 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alb |
albumin |
multiple interactions |
EXP ISO |
Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of ALB protein] ALB protein results in increased uptake of [Thioctic Acid binds to Gold] |
CTD |
PMID:24704557 PMID:28433809 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Apln |
apelin |
multiple interactions increases secretion increases expression |
ISO |
acadesine inhibits the reaction [Thioctic Acid results in increased expression of APLN mRNA]; acadesine inhibits the reaction [Thioctic Acid results in increased secretion of APLN protein] |
CTD |
PMID:21461750 |
|
NCBI chr X:134,856,719...134,866,210
Ensembl chr X:134,856,726...134,866,210
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO EXP |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of ATF4 mRNA]; Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of ATF4 protein] Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of ATF4 protein] |
CTD |
PMID:23892647 PMID:30605698 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of and results in increased cleavage of ATF6 protein]; Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of ATF6 mRNA] |
CTD |
PMID:23892647 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
ISO |
Thioctic Acid affects the reaction [Dietary Fats affects the expression of ATP1B1 mRNA] |
CTD |
PMID:27260466 |
|
NCBI chr13:82,737,161...82,757,681
Ensembl chr13:82,737,159...82,758,004
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
ISO |
Thioctic Acid promotes the reaction [Dietary Fats results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:27260466 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased localization of BAX protein]; Thioctic Acid inhibits the reaction [Zinc Oxide analog results in increased expression of BAX protein] Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of BAX mRNA] [Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of BAX mRNA; Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of BAX protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of BAX mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of BAX protein] |
CTD |
PMID:15735709 PMID:23830814 PMID:23892647 PMID:27544635 PMID:30605698 PMID:32061141 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of BBC3 mRNA] |
CTD |
PMID:23892647 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
[Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of BCHE protein; Hexachlorocyclohexane inhibits the reaction [[Resveratrol co-treated with Ascorbic Acid co-treated with Thioctic Acid co-treated with Vitamin E] results in increased activity of BCHE protein] |
CTD |
PMID:20663516 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases response to substance |
ISO EXP |
Thioctic Acid inhibits the reaction [Zinc deficiency results in decreased expression of BCL2 protein]; Thioctic Acid inhibits the reaction [Zinc Oxide analog results in decreased expression of BCL2 protein]; Thioctic Acid results in increased degradation of and results in decreased expression of BCL2 protein Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA] Thioctic Acid inhibits the reaction [[Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of BCL2 mRNA]; Thioctic Acid inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of BCL2 mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of BCL2 protein] BCL2 protein results in decreased susceptibility to Thioctic Acid |
CTD |
PMID:16990509 PMID:21600978 PMID:23830814 PMID:27260466 PMID:27544635 PMID:30605698 PMID:32061141 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of BRCA2 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
Thioctic Acid results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C4b |
complement C4B (Chido blood group) |
decreases expression |
ISO |
Thioctic Acid results in decreased expression of C4B mRNA |
CTD |
PMID:19555370 |
|
NCBI chr20:4,302,344...4,316,752
Ensembl chr20:4,302,344...4,316,715
|
|
G |
Calb2 |
calbindin 2 |
multiple interactions |
EXP |
Thioctic Acid affects the reaction [Propylthiouracil results in increased expression of CALB2 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Cadmium results in decreased expression of CALM1 mRNA] |
CTD |
PMID:26165643 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO EXP |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased activity of CASP3 protein]; Thioctic Acid inhibits the reaction [Cisplatin results in increased activity of CASP3 protein] Thioctic Acid results in increased expression of CASP3 protein modified form Thioctic Acid inhibits the reaction [Zinc Oxide analog results in increased activity of CASP3 protein] Thioctic Acid results in increased activity of CASP3 protein [Ryanodine co-treated with Thioctic Acid] results in decreased activity of CASP3 protein; Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of CASP3 protein modified form]; Thioctic Acid inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of CASP3 mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of CASP3 protein]; Thioctic Acid inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein]; Thioctic Acid inhibits the reaction [sodium arsenite results in increased expression of CASP3 mRNA]; Thioctic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein] |
CTD |
PMID:15909127 PMID:17079870 PMID:19951573 PMID:21062633 PMID:21763304 PMID:23892647 PMID:27544635 PMID:29214690 PMID:30605698 PMID:32061141 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in decreased expression of CASP8 mRNA Thioctic Acid inhibits the reaction [Zinc Oxide analog results in increased activity of CASP8 protein] |
CTD |
PMID:23830814 PMID:27544635 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
Thioctic Acid results in increased activity of CASP9 protein Thioctic Acid inhibits the reaction [Zinc Oxide analog results in increased activity of CASP9 protein] [Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of CASP9 mRNA; Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of CASP9 protein modified form]; Thioctic Acid inhibits the reaction [Streptozocin results in increased expression of CASP9 protein] |
CTD |
PMID:16990509 PMID:19951573 PMID:23830814 PMID:27544635 PMID:30605698 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions increases expression increases activity |
ISO EXP |
Thioctic Acid inhibits the reaction [Cisplatin results in decreased expression of CAT mRNA]; Thioctic Acid inhibits the reaction [Dietary Fats results in decreased activity of CAT protein] Thioctic Acid results in increased expression of CAT mRNA [Paraquat co-treated with Thioctic Acid] results in increased expression of CAT mRNA Thioctic Acid results in increased activity of CAT protein [acetovanillone results in increased susceptibility to Thioctic Acid] inhibits the reaction [Mitogens results in decreased activity of CAT protein]; Succimer promotes the reaction [Thioctic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]]; Thioctic Acid inhibits the reaction [Acetic Acid results in decreased activity of CAT protein]; Thioctic Acid inhibits the reaction [aroclor 1260 results in decreased activity of CAT protein]; Thioctic Acid inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Thioctic Acid inhibits the reaction [Ivermectin results in decreased activity of CAT protein]; Thioctic Acid inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]; Thioctic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Thioctic Acid inhibits the reaction [Valproic Acid results in decreased activity of CAT protein]; Thioctic Acid promotes the reaction [acetovanillone inhibits the reaction [Mitogens results in decreased activity of CAT protein]]; Thioctic Acid promotes the reaction [Succimer inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]] |
CTD |
PMID:15998567 PMID:19368863 PMID:19699728 PMID:19715735 PMID:21763304 PMID:22623521 PMID:23649336 PMID:26276312 PMID:27260466 PMID:27581792 PMID:28880400 PMID:29214690 PMID:29760339 PMID:32662911 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of CCL2 mRNA] |
CTD |
PMID:22488045 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Zinc deficiency results in decreased expression of CCND1 protein] |
CTD |
PMID:21600978 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD36 mRNA]] |
CTD |
PMID:21315065 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Thioctic Acid results in increased expression of CD86 protein |
CTD |
PMID:19033392 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cd8a |
CD8a molecule |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of CD8A mRNA |
CTD |
PMID:23830814 |
|
NCBI chr 4:99,217,640...99,243,352
Ensembl chr 4:99,239,115...99,243,351
|
|
G |
Cdx4 |
caudal type homeo box 4 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in increased expression of CDX4 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr X:74,165,172...74,173,758
Ensembl chr X:74,165,187...74,173,347
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Pilocarpine] results in increased activity of CHAT protein |
CTD |
PMID:19669875 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Cntf |
ciliary neurotrophic factor |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT1 protein]]; Thioctic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT3 protein]]; Thioctic Acid inhibits the reaction [Cadmium Chloride results in decreased activity of CNTF protein]; Thioctic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT1 protein]]; Thioctic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT3 protein]]; Thioctic Acid inhibits the reaction [Mercuric Chloride results in decreased activity of CNTF protein]; Thioctic Acid inhibits the reaction [Rotenone inhibits the reaction [CNTF results in increased phosphorylation of STAT1 protein]]; Thioctic Acid inhibits the reaction [Rotenone inhibits the reaction [CNTF results in increased phosphorylation of STAT3 protein]]; Thioctic Acid inhibits the reaction [Rotenone results in decreased activity of CNTF protein] |
CTD |
PMID:19635391 |
|
NCBI chr 1:229,599,009...229,601,032
Ensembl chr 1:229,599,009...229,601,032
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of COL1A1 mRNA; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of COL1A1 mRNA] |
CTD |
PMID:21251946 PMID:23830814 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA] |
CTD |
PMID:22464149 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:32061141 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
EXP |
Cyclosporine inhibits the reaction [Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of CRP protein]]; Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of CRP protein] |
CTD |
PMID:26276312 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cryaa |
crystallin, alpha A |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [naphthalene results in increased cleavage of CRYAA protein] |
CTD |
PMID:20597648 |
|
NCBI chr20:10,438,444...10,442,189
Ensembl chr20:10,438,444...10,442,187
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Doxorubicin results in decreased activity of CTSD protein] |
CTD |
PMID:12841641 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctss |
cathepsin S |
decreases expression |
ISO |
Thioctic Acid results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in increased expression of CYBB] |
CTD |
PMID:26518973 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Streptozocin affects the localization of CYCS protein] |
CTD |
PMID:19951573 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[CYP1A1 protein co-treated with CYP1A2 protein] affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; CYP1A1 protein affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]] |
CTD |
PMID:21932800 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP1A1 protein co-treated with CYP1A2 protein] affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]] Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:21932800 PMID:24120545 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:24120545 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:24120545 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:24120545 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:24120545 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Thioctic Acid affects the reaction [cyanoginosin LR affects the expression of CYP2E1 protein] |
CTD |
PMID:32061150 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:24120545 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dab1 |
DAB adaptor protein 1 |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of DAB1 mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO EXP |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of DDIT3 protein] Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein] |
CTD |
PMID:23892647 PMID:30605698 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of DGAT2 mRNA] |
CTD |
PMID:22464149 |
|
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of DIO1 mRNA] |
CTD |
PMID:27260466 |
|
NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
multiple interactions |
EXP |
[5-methoxyindole-2-carboxylic acid results in decreased activity of DLD protein] inhibits the reaction [3-dinitrobenzene results in decreased abundance of Thioctic Acid] |
CTD |
PMID:21551353 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 mRNA]; Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 protein] |
CTD |
PMID:20730801 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:23892647 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of EIF2S1 protein modified form] |
CTD |
PMID:30605698 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Zinc Oxide analog results in increased expression of FAS protein] |
CTD |
PMID:27544635 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in increased expression of FLT1 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Propylthiouracil] results in decreased expression of FOS mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxo3 |
forkhead box O3 |
decreases acetylation multiple interactions |
EXP |
Thioctic Acid results in decreased acetylation of FOXO3 protein [Thioctic Acid results in increased expression of [SIRT1 protein co-treated with SIRT3 protein]] which results in decreased acetylation of FOXO3 protein |
CTD |
PMID:22327056 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in increased expression of FRAS1 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr14:14,438,392...14,853,016
Ensembl chr14:14,439,082...14,689,554
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Cadmium Chloride results in decreased expression of FSHB protein] |
CTD |
PMID:20957662 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of GAD1 mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO EXP |
Thioctic Acid results in increased expression of GCLC mRNA Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of GCLC protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of GCLC mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of GCLC protein] |
CTD |
PMID:16249512 PMID:17940886 PMID:27298056 PMID:32061141 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO EXP |
Thioctic Acid results in increased expression of GCLM mRNA Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of GCLM mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of GCLM protein] |
CTD |
PMID:16249512 PMID:32061141 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Thioctic Acid results in decreased expression of GFAP mRNA |
CTD |
PMID:19555370 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of GGT1 protein] |
CTD |
PMID:24704557 |
|
NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP ISO |
Thioctic Acid inhibits the reaction [Cadmium affects the localization of GJA1 protein]; Thioctic Acid inhibits the reaction [Cadmium results in decreased expression of GJA1 mRNA] Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of GJA1 mRNA] |
CTD |
PMID:26165643 PMID:27260466 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gls |
glutaminase |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased activity of GLS protein] |
CTD |
PMID:32061141 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gnrhr |
gonadotropin releasing hormone receptor |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GNRHR mRNA] |
CTD |
PMID:28070105 |
|
NCBI chr14:23,480,462...23,498,450
Ensembl chr14:23,480,462...23,498,450
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of GPT protein] |
CTD |
PMID:24704557 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression multiple interactions |
ISO EXP |
Thioctic Acid results in increased expression of GPX1 mRNA Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of GPX1 protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of GPX1 mRNA] |
CTD |
PMID:23649336 PMID:32061141 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of GPX2 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression multiple interactions |
ISO |
Thioctic Acid results in increased expression of GPX3 mRNA [Paraquat co-treated with Thioctic Acid] results in increased expression of GPX3 mRNA |
CTD |
PMID:23649336 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gpx5 |
glutathione peroxidase 5 |
increases expression |
ISO |
Thioctic Acid results in increased expression of GPX5 mRNA |
CTD |
PMID:23649336 |
|
NCBI chr17:45,508,657...45,518,686
Ensembl chr17:45,467,015...45,518,686
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of GRIN1 mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of GRIN1 protein] |
CTD |
PMID:32061141 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of GRIN2A mRNA; Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of GRIN2A mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of GRIN2A protein] |
CTD |
PMID:31068541 PMID:32061141 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
Thioctic Acid results in increased phosphorylation of GSK3B protein Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of GSK3B mRNA] |
CTD |
PMID:19879292 PMID:27260466 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
EXP ISO |
Thioctic Acid inhibits the reaction [aroclor 1260 results in decreased expression of GSR protein]; Thioctic Acid inhibits the reaction [bisphenol A results in decreased activity of GSR protein]; Thioctic Acid inhibits the reaction [Lipopolysaccharides results in decreased activity of GSR protein] Thioctic Acid inhibits the reaction [cyanoginosin LR results in decreased activity of GSR protein] Thioctic Acid results in increased expression of GSR mRNA |
CTD |
PMID:19699728 PMID:22623521 PMID:23649336 PMID:27581792 PMID:32061150 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gss |
glutathione synthetase |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased activity of GSS protein] |
CTD |
PMID:32061141 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of GSTM1 mRNA [Dietary Fats co-treated with Thioctic Acid] results in increased expression of GSTM1 mRNA |
CTD |
PMID:18367378 PMID:23830814 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm7 |
glutathione S-transferase, mu 7 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of GSTM7 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr 2:210,720,719...210,726,179
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
EXP |
[Thioctic Acid promotes the reaction [JUN protein binds to GSTP1 enhancer]] which results in increased expression of GSTP1 mRNA; [Thioctic Acid promotes the reaction [NFE2L2 protein binds to GSTP1 enhancer]] which results in increased expression of GSTP1 mRNA; Thioctic Acid promotes the reaction [JUN protein binds to GSTP1 enhancer]; Thioctic Acid promotes the reaction [NFE2L2 protein binds to GSTP1 enhancer]; Thioctic Acid results in increased expression of and results in increased activity of GSTP1 protein Thioctic Acid results in increased expression of GSTP1 mRNA |
CTD |
PMID:20237067 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Lipopolysaccharides results in decreased activity of GUSB protein] |
CTD |
PMID:19699728 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[Thioctic Acid binds to Gold] which results in increased expression of HAVCR1 protein |
CTD |
PMID:28433809 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[Paraquat co-treated with Thioctic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Thioctic Acid] results in increased expression of HMOX1 protein; Thioctic Acid inhibits the reaction [Arsenic Trioxide results in increased expression of HMOX1 mRNA]; Thioctic Acid inhibits the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]; Thioctic Acid inhibits the reaction [Polychlorinated Biphenyls analog results in increased expression of HMOX1 protein]; Thioctic Acid promotes the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of HMOX1 mRNA]; Thioctic Acid promotes the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of HMOX1 protein] Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of HMOX1 mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of HMOX1 protein] Thioctic Acid results in increased expression of HMOX1 mRNA; Thioctic Acid results in increased expression of HMOX1 protein Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 mRNA]; Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 protein]; Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of HMOX1 mRNA] |
CTD |
PMID:19033392 PMID:21315065 PMID:22488045 PMID:23649336 PMID:23942037 PMID:24361488 PMID:27260466 PMID:27298056 PMID:30758914 PMID:31319135 PMID:32061141 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hs1bp3 |
HCLS1 binding protein 3 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of HS1BP3 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr 6:33,517,711...33,548,015
Ensembl chr 6:33,517,769...33,548,034
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Ivermectin results in increased expression of HSPA1A mRNA] |
CTD |
PMID:28880400 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO EXP |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of HSPA5 protein] Thioctic Acid inhibits the reaction [cadmium acetate results in increased expression of HSPA5 protein] |
CTD |
PMID:23892647 PMID:30605698 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Ivermectin results in increased expression of IGFBP3 mRNA] |
CTD |
PMID:28880400 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in decreased expression of IL10]; Thioctic Acid promotes the reaction [Carrageenan results in increased expression of IL10 mRNA] |
CTD |
PMID:19735303 PMID:26518973 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of IL1A mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of IL1B mRNA; Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in increased expression of IL1B] Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP3 protein] |
CTD |
PMID:23830814 PMID:24975507 PMID:26518973 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL2 protein] |
CTD |
PMID:21195065 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il22ra2 |
interleukin 22 receptor subunit alpha 2 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of IL22RA2 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr 1:15,084,136...15,107,423
Ensembl chr 1:15,093,599...15,106,954
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of IL4 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of IL6 mRNA] [Thioctic Acid binds to Gold] which results in increased expression of IL6 protein acetovanillone promotes the reaction [Thioctic Acid inhibits the reaction [Mitogens results in increased expression of IL6 protein]]; Thioctic Acid inhibits the reaction [Mitogens results in increased expression of IL6 protein]; Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in increased expression of IL6]; Thioctic Acid promotes the reaction [acetovanillone inhibits the reaction [Mitogens results in increased expression of IL6 protein]] |
CTD |
PMID:22488045 PMID:26518973 PMID:28433809 PMID:29760339 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Glucose results in increased expression of INS protein] |
CTD |
PMID:16505238 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Thioctic Acid results in increased sumoylation of and results in decreased activity of IRF1 protein |
CTD |
PMID:24975507 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression increases activity |
EXP |
[Thioctic Acid promotes the reaction [JUN protein binds to GSTP1 enhancer]] which results in increased expression of GSTP1 mRNA; Thioctic Acid promotes the reaction [JUN protein binds to GSTP1 enhancer] Thioctic Acid results in increased expression of JUN protein Thioctic Acid results in increased activity of JUN protein |
CTD |
PMID:20237067 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression |
ISO |
Thioctic Acid results in increased expression of KEAP1 protein |
CTD |
PMID:19033392 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Ldhc |
lactate dehydrogenase C |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [aroclor 1260 results in decreased expression of LDHC protein]; Thioctic Acid inhibits the reaction [Lipopolysaccharides results in decreased expression of LDHC protein] |
CTD |
PMID:21195065 PMID:27581792 |
|
NCBI chr 1:102,914,875...102,931,843
Ensembl chr 1:102,915,191...102,931,839
|
|
G |
Lep |
leptin |
decreases secretion decreases expression |
ISO EXP |
Thioctic Acid results in decreased secretion of LEP protein Thioctic Acid results in decreased expression of LEP mRNA; Thioctic Acid results in decreased expression of LEP protein |
CTD |
PMID:21351249 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Cadmium Chloride results in decreased expression of LHB protein]; Thioctic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LHB mRNA] |
CTD |
PMID:20957662 PMID:28070105 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions increases phosphorylation |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Thioctic Acid results in increased phosphorylation of LIPE protein] |
CTD |
PMID:22941773 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects activity multiple interactions |
EXP |
Thioctic Acid affects the activity of MAPK1 protein Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased phosphorylation of MAPK1 protein]; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of MAPK1 protein] |
CTD |
PMID:15909127 PMID:21251946 PMID:32061141 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of MAPK14 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of MAPK3 mRNA; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased phosphorylation of MAPK3 protein]; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of MAPK3 protein] |
CTD |
PMID:21251946 PMID:23830814 PMID:32061141 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of MAPK8 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
EXP |
Cyclosporine inhibits the reaction [Thioctic Acid promotes the reaction [Acetic Acid results in increased expression of MIR21 mRNA]]; Thioctic Acid promotes the reaction [Acetic Acid results in increased expression of MIR21 mRNA] |
CTD |
PMID:26276312 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mir210 |
microRNA 210 |
multiple interactions |
EXP |
[Cyclosporine co-treated with Thioctic Acid] promotes the reaction [Acetic Acid results in increased expression of MIR210 mRNA]; Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of MIR210 mRNA]; Thioctic Acid inhibits the reaction [Cyclosporine inhibits the reaction [Acetic Acid results in increased expression of MIR210 mRNA]] |
CTD |
PMID:26276312 |
|
NCBI chr 1:214,208,355...214,208,464
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of MMP12 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr 8:5,594,717...5,616,494
Ensembl chr 8:5,606,592...5,616,493
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] |
CTD |
PMID:24975507 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of MMP2 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Thioctic Acid inhibits the reaction [IL1B protein results in increased expression of MMP3 protein] |
CTD |
PMID:24975507 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA]] |
CTD |
PMID:21315065 |
|
NCBI chr16:56,817,714...56,900,025
Ensembl chr16:56,813,791...56,900,052
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Thioctic Acid] results in decreased expression of MT1 mRNA |
CTD |
PMID:18367378 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Thioctic Acid] results in decreased expression of MVD mRNA |
CTD |
PMID:18367378 |
|
NCBI chr19:55,258,910...55,268,933
Ensembl chr19:55,258,905...55,268,951
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Zinc deficiency results in decreased expression of MYC protein] |
CTD |
PMID:21600978 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in increased expression of NCF1] |
CTD |
PMID:26518973 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects localization increases expression increases activity decreases expression |
ISO EXP |
[Paraquat co-treated with Thioctic Acid] results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 protein affects the reaction [Thioctic Acid results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [Thioctic Acid results in increased expression of NQO1 protein]; Thioctic Acid inhibits the reaction [Acrolein results in decreased expression of NFE2L2 protein]; Thioctic Acid inhibits the reaction [Polychlorinated Biphenyls analog results in increased expression of NFE2L2 protein]; Thioctic Acid promotes the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which affects the localization of NFE2L2 protein]; Thioctic Acid promotes the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of NFE2L2 mRNA]; Thioctic Acid promotes the reaction [Paraquat results in increased expression of NFE2L2 mRNA]; Thioctic Acid results in increased expression of and affects the localization of NFE2L2 protein Thioctic Acid affects the localization of NFE2L2 protein Thioctic Acid results in increased expression of NFE2L2 mRNA; Thioctic Acid results in increased expression of NFE2L2 protein Thioctic Acid results in increased activity of NFE2L2 protein [Thioctic Acid promotes the reaction [NFE2L2 protein binds to GSTP1 enhancer]] which results in increased expression of GSTP1 mRNA; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of NFE2L2 mRNA]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of NFE2L2 protein]; Thioctic Acid promotes the reaction [NFE2L2 protein binds to GSTP1 enhancer] Thioctic Acid results in decreased expression of NFE2L2 mRNA; Thioctic Acid results in decreased expression of NFE2L2 protein [Thioctic Acid co-treated with cyanoginosin LR] results in increased expression of NFE2L2 protein; Thioctic Acid inhibits the reaction [Arsenic Trioxide results in increased expression of NFE2L2 mRNA]; Thioctic Acid inhibits the reaction [Arsenic Trioxide results in increased expression of NFE2L2 protein]; Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:17197552 PMID:18258206 PMID:20237067 PMID:22488045 PMID:23649336 PMID:24361488 PMID:27260466 PMID:27298056 PMID:30758914 PMID:31319135 PMID:32061141 PMID:32061150 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
Thioctic Acid inhibits the reaction [Zinc deficiency affects the localization of NFKB1 protein] [Thioctic Acid co-treated with Propylthiouracil] results in decreased expression of NFKB1 mRNA |
CTD |
PMID:21600978 PMID:31068541 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Cisplatin results in increased expression of NOS2]; Thioctic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15453632 PMID:21763304 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of NOS3 mRNA] |
CTD |
PMID:27260466 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
acetovanillone promotes the reaction [Thioctic Acid inhibits the reaction [Mitogens results in increased expression of NOX1 mRNA]]; Thioctic Acid inhibits the reaction [Mitogens results in increased expression of NOX1 mRNA]; Thioctic Acid promotes the reaction [acetovanillone inhibits the reaction [Mitogens results in increased expression of NOX1 mRNA]] |
CTD |
PMID:29760339 |
|
NCBI chr X:104,909,328...104,932,508
Ensembl chr X:104,909,326...104,932,508
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
acetovanillone promotes the reaction [Thioctic Acid inhibits the reaction [Mitogens results in increased expression of NOX4 mRNA]]; Thioctic Acid inhibits the reaction [Mitogens results in increased expression of NOX4 mRNA]; Thioctic Acid promotes the reaction [acetovanillone inhibits the reaction [Mitogens results in increased expression of NOX4 mRNA]] |
CTD |
PMID:29760339 |
|
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
ISO EXP |
Thioctic Acid results in increased activity of NQO1 protein Thioctic Acid results in increased expression of NQO1 mRNA; Thioctic Acid results in increased expression of NQO1 protein [Paraquat co-treated with Thioctic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Thioctic Acid] results in increased expression of NQO1 protein; NFE2L2 protein affects the reaction [Thioctic Acid results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [Thioctic Acid results in increased expression of NQO1 protein]; Thioctic Acid promotes the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of NQO1 mRNA]; Thioctic Acid promotes the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of NQO1 protein] [Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of NQO1 mRNA; Thioctic Acid inhibits the reaction [Propylthiouracil results in increased expression of NQO1 mRNA] |
CTD |
PMID:12180195 PMID:17940886 PMID:19033392 PMID:23649336 PMID:23830814 PMID:30758914 PMID:31068541 PMID:31319135 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Propylthiouracil results in increased expression of OTX2 mRNA] |
CTD |
PMID:31068541 |
|
NCBI chr15:25,500,037...25,511,619
Ensembl chr15:25,502,019...25,505,691
|
|
G |
Pah |
phenylalanine hydroxylase |
decreases expression |
ISO |
Thioctic Acid results in decreased expression of PAH mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 7:28,066,639...28,129,772
Ensembl chr 7:28,066,635...28,129,769
|
|
G |
Pcdhb6l |
protocadherin beta-6-like |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of PCDHB6 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr18:30,512,507...30,518,524
Ensembl chr18:30,515,962...30,518,352
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of PCNA protein] |
CTD |
PMID:21251946 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Plaat3 |
phospholipase A and acyltransferase 3 |
decreases expression decreases activity |
ISO |
Thioctic Acid results in decreased expression of PLAAT3 mRNA Thioctic Acid results in decreased activity of PLAAT3 protein |
CTD |
PMID:22941773 |
|
NCBI chr 1:222,844,238...222,877,180
Ensembl chr 1:222,844,144...222,877,193
|
|
G |
Plin1 |
perilipin 1 |
increases phosphorylation |
ISO |
Thioctic Acid results in increased phosphorylation of PLIN1 protein |
CTD |
PMID:22941773 |
|
NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases activity |
ISO |
[CYP1A1 protein co-treated with CYP1A2 protein] affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]]; [Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; CYP1A1 protein affects the reaction [[Thioctic Acid results in decreased activity of POR protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]] Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] |
CTD |
PMID:16391466 PMID:21932800 PMID:24120545 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA] |
CTD |
PMID:22464149 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Dietary Fats] results in increased expression of PPARG mRNA |
CTD |
PMID:22464149 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO EXP |
[Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of PPARGC1A mRNA] Thioctic Acid results in increased expression of PPARGC1A protein |
CTD |
PMID:20414966 PMID:22464149 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
multiple interactions decreases acetylation |
EXP |
[Thioctic Acid results in increased expression of [SIRT1 protein co-treated with SIRT3 protein]] which results in decreased acetylation of PPARGC1B protein; Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of PPARGC1B mRNA] Thioctic Acid results in decreased acetylation of PPARGC1B protein |
CTD |
PMID:22327056 PMID:22464149 |
|
NCBI chr18:56,626,725...56,650,524
Ensembl chr18:56,626,712...56,728,968
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Cyclosporine co-treated with Thioctic Acid] promotes the reaction [Acetic Acid results in increased expression of PTGS2 mRNA]; Cyclosporine inhibits the reaction [Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of PTGS2 mRNA]]; Thioctic Acid inhibits the reaction [[Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Cyclosporine inhibits the reaction [Acetic Acid results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:19735303 PMID:23830814 PMID:26276312 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases phosphorylation |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased phosphorylation of RELA protein] Thioctic Acid results in decreased phosphorylation of RELA protein |
CTD |
PMID:22488045 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Reln |
reelin |
multiple interactions |
EXP |
[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of RELN mRNA |
CTD |
PMID:31068541 |
|
NCBI chr 4:9,347,533...9,774,257
Ensembl chr 4:9,347,528...9,773,670
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
EXP |
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]]; Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein] |
CTD |
PMID:23880158 |
|
NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
|
|
G |
Sema5a |
semaphorin 5A |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of SEMA5A mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr 2:85,377,318...85,808,970
Ensembl chr 2:85,377,318...85,808,970
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of SERPINH1 mRNA] |
CTD |
PMID:24704557 |
|
NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression multiple interactions |
EXP |
Thioctic Acid results in increased expression of SIRT1 protein [Thioctic Acid results in increased expression of [SIRT1 protein co-treated with SIRT3 protein]] which results in decreased acetylation of FOXO3 protein; [Thioctic Acid results in increased expression of [SIRT1 protein co-treated with SIRT3 protein]] which results in decreased acetylation of PPARGC1B protein; Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of SIRT1 mRNA] |
CTD |
PMID:22327056 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression |
EXP |
[Thioctic Acid results in increased expression of [SIRT1 protein co-treated with SIRT3 protein]] which results in decreased acetylation of FOXO3 protein; [Thioctic Acid results in increased expression of [SIRT1 protein co-treated with SIRT3 protein]] which results in decreased acetylation of PPARGC1B protein; Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of SIRT3 mRNA] Thioctic Acid results in increased expression of SIRT3 protein |
CTD |
PMID:22327056 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
multiple interactions affects activity |
EXP |
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]]; [Furosemide results in decreased activity of SLC12A2 protein] promotes the reaction [Thioctic Acid results in decreased activity of Ammonia] Thioctic Acid affects the activity of SLC12A2 protein |
CTD |
PMID:23880158 |
|
NCBI chr18:52,917,124...52,985,281
Ensembl chr18:52,917,124...52,985,261
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of SLC1A1 protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of SLC1A1 mRNA] |
CTD |
PMID:32061141 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:23892647 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
increases transport multiple interactions |
ISO EXP |
SLC5A6 results in increased transport of Thioctic Acid Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Biotin]; Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Pantothenic Acid] Sodium affects the reaction [SLC5A6 results in increased transport of Thioctic Acid] |
CTD |
PMID:9516450 PMID:10329687 |
|
NCBI chr 6:26,685,823...26,697,110
Ensembl chr 6:26,686,033...26,697,116
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [methylmercuric chloride results in decreased expression of SLC7A11 protein]; Thioctic Acid inhibits the reaction [methylmercuric chloride results in increased expression of SLC7A11 mRNA] |
CTD |
PMID:32061141 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Thioctic Acid inhibits the reaction [Rotenone results in increased expression of SNCA protein] |
CTD |
PMID:20414966 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [sodium arsenite results in decreased activity of SOD1 protein]; Thioctic Acid inhibits the reaction [Sodium Chloride, Dietary results in decreased expression of SOD1] |
CTD |
PMID:15804455 PMID:26518973 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases activity |
EXP ISO |
Thioctic Acid inhibits the reaction [sodium arsenite results in decreased activity of SOD2 protein]; Thioctic Acid inhibits the reaction [Streptozocin results in decreased activity of SOD2 protein] [Thioctic Acid co-treated with Dietary Fats] results in decreased expression of SOD2 mRNA Thioctic Acid results in increased activity of SOD2 protein |
CTD |
PMID:15804455 PMID:19951573 PMID:22327056 PMID:27260466 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
Thioctic Acid results in increased phosphorylation of and results in decreased activity of SP1 protein |
CTD |
PMID:21351249 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:22464149 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STAR mRNA] |
CTD |
PMID:28070105 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Thioctic Acid affects the reaction [Zinc deficiency affects the phosphorylation of STAT1 protein]; Thioctic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT1 protein]]; Thioctic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT1 protein]]; Thioctic Acid inhibits the reaction [Rotenone inhibits the reaction [CNTF results in increased phosphorylation of STAT1 protein]]; Thioctic Acid inhibits the reaction [Zinc deficiency affects the localization of STAT1 protein] |
CTD |
PMID:19635391 PMID:28086195 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT3 protein]]; Thioctic Acid inhibits the reaction [Mercuric Chloride inhibits the reaction [CNTF results in increased phosphorylation of STAT3 protein]]; Thioctic Acid inhibits the reaction [Rotenone inhibits the reaction [CNTF results in increased phosphorylation of STAT3 protein]]; Thioctic Acid inhibits the reaction [Zinc deficiency affects the localization of STAT3 protein] |
CTD |
PMID:19635391 PMID:28086195 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
increases expression |
ISO |
Thioctic Acid results in increased expression of SUMO1 protein |
CTD |
PMID:24975507 |
|
NCBI chr 9:66,453,428...66,483,614
Ensembl chr 9:66,453,438...66,483,614
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Cyclosporine inhibits the reaction [Thioctic Acid promotes the reaction [Acetic Acid results in increased expression of TGFB1 mRNA]]; Thioctic Acid inhibits the reaction [Mitogens results in increased expression of TGFB1 protein]; Thioctic Acid inhibits the reaction [Streptozocin results in increased expression of TGFB1 mRNA]; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]; Thioctic Acid inhibits the reaction [Thioacetamide results in increased expression of TGFB1 protein]; Thioctic Acid promotes the reaction [Acetic Acid results in increased expression of TGFB1 mRNA] |
CTD |
PMID:15309289 PMID:21251946 PMID:24704557 PMID:26276312 PMID:29760339 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb1i1 |
transforming growth factor beta 1 induced transcript 1 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of TGFB1I1 mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr 1:199,664,039...199,670,970
Ensembl chr 1:199,664,173...199,670,961
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of TGFB2 mRNA; [Thioctic Acid co-treated with Propylthiouracil] results in increased expression of TGFB2 mRNA |
CTD |
PMID:23830814 PMID:31068541 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Dietary Fats results in increased expression of THRA mRNA] |
CTD |
PMID:27260466 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of TNF mRNA; acetovanillone promotes the reaction [Thioctic Acid inhibits the reaction [Mitogens results in increased expression of TNF protein]]; Cyclosporine inhibits the reaction [Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of TNF protein]]; Thioctic Acid inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Thioctic Acid inhibits the reaction [Mitogens results in increased expression of TNF protein]; Thioctic Acid inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Thioctic Acid promotes the reaction [acetovanillone inhibits the reaction [Mitogens results in increased expression of TNF protein]] |
CTD |
PMID:15309289 PMID:23830814 PMID:26276312 PMID:29760339 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of TNFRSF10B mRNA] |
CTD |
PMID:23608068 |
|
NCBI chr15:51,433,853...51,464,215
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:23830814 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein] |
CTD |
PMID:21034734 |
|
NCBI chr 1:72,882,806...72,886,490
Ensembl chr 1:72,882,806...72,886,488
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Methotrexate results in increased expression of TP53 protein] |
CTD |
PMID:19900424 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of TRIB3 mRNA]; Thioctic Acid inhibits the reaction [Potassium Dichromate results in increased expression of TRIB3 mRNA] |
CTD |
PMID:23608068 PMID:23892647 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] results in increased expression of TXN1 mRNA; Thioctic Acid inhibits the reaction [Propylthiouracil results in increased expression of TXN1 mRNA] |
CTD |
PMID:23830814 PMID:31068541 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases reduction multiple interactions |
ISO EXP |
TXNRD1 protein results in increased reduction of Thioctic Acid Thioctic Acid inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein] |
CTD |
PMID:20810785 PMID:21172426 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Dietary Fats results in decreased expression of UCP2 mRNA] |
CTD |
PMID:22327056 PMID:22464149 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
EXP ISO |
Cyclosporine inhibits the reaction [Thioctic Acid results in increased expression of VEGFA mRNA]; Thioctic Acid inhibits the reaction [Cyclosporine results in increased expression of VEGFA mRNA]; Thioctic Acid inhibits the reaction [Streptozocin results in decreased expression of VEGFA mRNA] Thioctic Acid inhibits the reaction [arsenic trioxide results in increased expression of VEGFA mRNA] |
CTD |
PMID:11596663 PMID:22488045 PMID:26276312 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
Thioctic Acid inhibits the reaction [Valproic Acid results in increased activity of XDH protein] |
CTD |
PMID:32662911 |
|
NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
sapropterin inhibits the reaction [Fructose results in decreased expression of ADIPOQ mRNA]; sapropterin inhibits the reaction [Fructose results in decreased expression of ADIPOQ protein] |
CTD |
PMID:17098227 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
APP gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin; GW 501516 inhibits the reaction [APP gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin] |
CTD |
PMID:22886847 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
sapropterin inhibits the reaction [Methotrexate results in increased expression of CDKN1A protein] |
CTD |
PMID:22183962 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Epo |
erythropoietin |
multiple interactions increases abundance |
ISO |
EPO protein inhibits the reaction [GCH1 mutant form results in decreased abundance of sapropterin] EPO protein results in increased abundance of sapropterin EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7,8-dihydrobiopterin]; EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides]; EPO protein inhibits the reaction [HPH1 gene mutant form results in increased oxidation of sapropterin] |
CTD |
PMID:25041251 PMID:25490417 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
decreases abundance affects abundance multiple interactions increases chemical synthesis |
ISO |
GCH1 mutant form results in decreased abundance of sapropterin GCH1 protein affects the abundance of sapropterin [GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7,8-dihydrobiopterin; [resveratrol results in increased expression of GCH1 mRNA] which results in increased abundance of sapropterin; EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7,8-dihydrobiopterin]; GCH1 gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin GCH1 protein results in increased chemical synthesis of sapropterin EPO protein inhibits the reaction [GCH1 mutant form results in decreased abundance of sapropterin] |
CTD |
PMID:14551046 PMID:20610621 PMID:21963838 PMID:25041251 PMID:25490417 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases activity multiple interactions |
ISO |
sapropterin results in increased activity of NOS3 protein sapropterin deficiency inhibits the reaction [NOS3 protein results in increased abundance of Superoxides]; sapropterin deficiency promotes the reaction [NOS3 protein results in increased abundance of Superoxides] [NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides; EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides] |
CTD |
PMID:19011239 PMID:23753407 PMID:25490417 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Sct |
secretin |
increases abundance |
ISO |
SCT protein results in increased abundance of sapropterin |
CTD |
PMID:16168596 |
|
NCBI chr 1:214,264,865...214,277,437
Ensembl chr 1:214,264,754...214,265,668
|
|
G |
Snca |
synuclein alpha |
increases abundance |
ISO |
SNCA mutant form results in increased abundance of sapropterin |
CTD |
PMID:24148766 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
sapropterin inhibits the reaction [Methotrexate results in increased expression of TP53 protein] |
CTD |
PMID:22183962 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in decreased phosphorylation of AKT1 protein]; [Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased cleavage of AKT1 protein]; Biotin inhibits the reaction [Aluminum Chloride results in decreased phosphorylation of AKT1 protein]; Biotin inhibits the reaction [Aluminum Chloride results in increased cleavage of AKT1 protein] |
CTD |
PMID:32383521 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of APP protein]; Biotin inhibits the reaction [Aluminum Chloride results in increased expression of APP protein] |
CTD |
PMID:32383521 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
decreases expression |
ISO |
Biotin results in decreased expression of CXCL11 mRNA |
CTD |
PMID:15219929 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Biotin results in increased expression of and results in increased activity of CYP1B1 protein Biotin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:15219929 PMID:15333708 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] |
CTD |
PMID:9143349 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
multiple interactions |
ISO |
[Chromium co-treated with Biotin] results in decreased expression of HBA1 protein modified form; [chromium tripicolinate co-treated with Biotin] results in decreased expression of HBA1 protein modified form |
CTD |
PMID:17684468 |
|
NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
|
|
G |
Herc4 |
HECT and RLD domain containing E3 ubiquitin protein ligase 4 |
increases expression |
ISO |
Biotin results in increased expression of HERC4 mRNA |
CTD |
PMID:15219929 |
|
NCBI chr20:26,755,948...26,831,267
Ensembl chr20:26,755,911...26,830,931
|
|
G |
Hira |
histone cell cycle regulator |
decreases expression |
ISO |
Biotin results in decreased expression of HIRA mRNA |
CTD |
PMID:15219929 |
|
NCBI chr11:86,168,196...86,276,430
Ensembl chr11:86,168,196...86,276,430
|
|
G |
Ighg1 |
immunoglobulin heavy constant gamma 1 |
increases expression |
ISO |
Biotin results in increased expression of IGHG1 mRNA |
CTD |
PMID:15219929 |
|
NCBI chr 6:139,140,572...139,784,388
Ensembl chr 6:139,140,679...139,142,218
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; Biotin inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein] |
CTD |
PMID:32383521 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of IL6 protein]; Biotin inhibits the reaction [Aluminum Chloride results in increased expression of IL6 protein] |
CTD |
PMID:32383521 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride affects the phosphorylation of IRS1 protein]; Biotin inhibits the reaction [Aluminum Chloride affects the phosphorylation of IRS1 protein] |
CTD |
PMID:32383521 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
decreases expression |
ISO |
Biotin results in decreased expression of LAMP1 mRNA |
CTD |
PMID:15219929 |
|
NCBI chr16:81,689,576...81,714,341
Ensembl chr16:81,689,335...81,714,419
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Biotin results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Sele |
selectin E |
affects binding |
ISO |
[Acetylglucosamine analog binds to Biotin] which binds to SELE protein |
CTD |
PMID:12191509 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Sell |
selectin L |
affects binding |
EXP |
[Acetylglucosamine analog binds to Biotin] which binds to SELL protein |
CTD |
PMID:12191509 |
|
NCBI chr13:82,369,820...82,387,774
Ensembl chr13:82,369,493...82,387,631
|
|
G |
Selp |
selectin P |
affects binding |
ISO |
[Acetylglucosamine analog binds to Biotin] which binds to SELP protein |
CTD |
PMID:12191509 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Slc5a6 |
solute carrier family 5 member 6 |
affects expression increases transport multiple interactions increases uptake |
ISO EXP |
Biotin affects the expression of SLC5A6 mRNA; Biotin affects the expression of SLC5A6 protein SLC5A6 results in increased transport of Biotin Sodium affects the reaction [SLC5A6 results in increased transport of Biotin]; Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Biotin] 2,4-Dinitrophenol inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; 4-Chloromercuribenzenesulfonate inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Azides inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; calmidazolium inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; chelerythrine inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Gramicidin inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Iodoacetates inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Ouabain inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Probenecid inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Sodium affects the reaction [SLC5A6 results in increased transport of Biotin]; Sodium promotes the reaction [SLC5A6 protein results in increased transport of Biotin]; Staurosporine inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]; Tetradecanoylphorbol Acetate promotes the reaction [SLC5A6 protein results in increased transport of Biotin]; Trifluoperazine inhibits the reaction [SLC5A6 protein results in increased transport of Biotin] SLC5A6 results in increased uptake of Biotin SLC5A6 protein results in increased transport of Biotin; SLC5A6 results in increased transport of Biotin |
CTD |
PMID:9516450 PMID:10329687 PMID:10516089 PMID:12646417 PMID:15561972 |
|
NCBI chr 6:26,685,823...26,697,110
Ensembl chr 6:26,686,033...26,697,116
|
|
G |
Tmprss15 |
transmembrane serine protease 15 |
increases expression |
ISO |
Biotin results in increased expression of TMPRSS15 mRNA |
CTD |
PMID:15219929 |
|
NCBI chr11:17,561,591...17,684,903
Ensembl chr11:17,561,596...17,684,903
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[Biotin co-treated with coenzyme Q10] inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein]; Biotin inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein] |
CTD |
PMID:32383521 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tpr |
translocated promoter region, nuclear basket protein |
increases expression |
ISO |
Biotin results in increased expression of TPR mRNA |
CTD |
PMID:15219929 |
|
NCBI chr13:67,611,685...67,672,833
Ensembl chr13:67,611,708...67,672,827
|
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
cobamamide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
|
G |
Ndufa9 |
NADH:ubiquinone oxidoreductase subunit A9 |
multiple interactions |
ISO |
Flavin-Adenine Dinucleotide binds to and results in increased activity of NDUFA9 protein |
CTD |
PMID:25526675 |
|
NCBI chr 4:159,371,263...159,399,636
Ensembl chr 4:159,371,259...159,399,634
|
|
G |
Rfk |
riboflavin kinase |
increases abundance |
ISO |
RFK protein results in increased abundance of Flavin-Adenine Dinucleotide |
CTD |
PMID:21308351 |
|
NCBI chr 1:236,494,221...236,501,733
Ensembl chr 1:236,494,221...236,501,733
|
|
G |
Slc52a3 |
solute carrier family 52 member 3 |
multiple interactions |
EXP |
Flavin-Adenine Dinucleotide inhibits the reaction [SLC52A3 protein results in increased transport of Riboflavin] |
CTD |
PMID:19122205 |
|
NCBI chr 3:147,503,266...147,517,935
Ensembl chr 3:147,511,406...147,516,455
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression multiple interactions |
ISO |
Heme results in decreased expression of ALAS1 protein MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Heme binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:98,668,231...98,689,471
Ensembl chr 9:98,668,231...98,684,900
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:27,835,346...27,919,285
Ensembl chr 6:27,887,797...27,915,563
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,552,550...119,577,796
Ensembl chr 3:119,561,290...119,577,806
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:100,829,593...100,840,498
Ensembl chr 9:100,829,552...100,840,504
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,936,721...3,995,740
Ensembl chr15:3,936,786...3,995,915
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:81,783,349...81,808,815
Ensembl chr 9:81,783,349...81,808,805
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:8,876,090...8,894,345
Ensembl chr 5:8,876,044...8,894,339
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:86,852,682...86,885,233
Ensembl chr11:86,852,711...86,885,224
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:88,498,271...88,533,730
Ensembl chr10:88,498,238...88,533,829
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:63,268,106...63,291,125
Ensembl chr X:63,268,037...63,292,092
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
Heme results in increased expression of F3 mRNA Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA Heme results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:149,984,206...149,988,744
Ensembl chr 4:149,984,206...149,988,295
|
|
G |
Gfod1 |
glucose-fructose oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:110,042,853...110,140,756
Ensembl chr 3:110,042,853...110,140,756
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:168,832,937...168,851,650
Ensembl chr 4:168,832,910...168,851,652
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,860,578...135,870,535
Ensembl chr 5:135,860,675...135,868,495
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:10,134,726...10,152,976
Ensembl chr17:10,137,974...10,152,956
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases degradation increases metabolic processing decreases expression decreases abundance increases expression |
ISO EXP |
[HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased metabolism of Heme Heme results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased abundance of Heme [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:47,644,071...47,651,487
Ensembl chr13:47,644,071...47,647,715
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:89,919,570...89,929,774
Ensembl chr13:89,919,667...89,929,770
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:87,342,514...87,351,045
Ensembl chr10:87,342,619...87,351,045
|
|
G |
Lep |
leptin |
multiple interactions increases abundance |
ISO |
cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]; tin mesoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]] |
CTD |
PMID:23839791 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
LOC100364500 |
RT1 class I, locus CE11-like |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:2,704,153...2,707,111
Ensembl chr20:2,704,148...2,707,120
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions increases secretion |
ISO |
SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:91,772,927...91,827,231
Ensembl chr13:91,773,004...91,776,397
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions decreases response to substance |
ISO |
[Heme co-treated with HPX protein] affects the activity of MT1 promoter MT1A protein results in decreased susceptibility to Heme |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:125,124,743...125,175,857
Ensembl chr 1:125,124,743...125,175,857
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein |
CTD |
PMID:23355332 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:126,254,090...126,259,204
Ensembl chr 5:126,254,142...126,259,200
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:137,618,891...137,923,385
Ensembl chr 3:137,618,898...137,925,605
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:167,309,021...167,335,550
Ensembl chr 1:167,309,051...167,334,741
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:111,998,204...112,048,847
Ensembl chr 9:111,998,203...112,027,240
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:91,451,890...91,500,675
Ensembl chr10:91,451,865...91,500,661
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:198,112,104...198,120,202
Ensembl chr 2:198,112,076...198,120,120
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:113,373,569...113,570,774
Ensembl chr13:113,373,578...113,571,648
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:11,253,424...11,271,873
Ensembl chr 3:11,254,026...11,271,872
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:140,822,141...140,835,244
Ensembl chr 5:140,822,141...140,834,959
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:74,173,809...74,291,188
Ensembl chr18:74,174,936...74,292,921
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:135,348,799...135,360,204
Ensembl chr X:135,348,436...135,360,203
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:20,435,098...20,439,206
Ensembl chr16:20,435,101...20,439,206
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:151,691,498...151,724,723
Ensembl chr 3:151,691,514...151,724,654
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:122,700,849...122,710,907
Ensembl chr 7:122,700,854...122,709,935
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Heme analog affects the localization of RELA protein |
CTD |
PMID:23355332 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:140,552,704...140,556,980
Ensembl chr 7:140,552,733...140,556,639
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:111,565,646...111,587,184
Ensembl chr 3:111,565,650...111,587,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:196,495,867...196,527,412
Ensembl chr 2:196,495,867...196,527,127
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:90,056,726...90,075,159
Ensembl chr13:90,058,127...90,075,144
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
|
|
G |
Smarcb1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:13,679,955...13,702,821
Ensembl chr20:13,680,716...13,704,931
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:165,600,934...165,629,415
Ensembl chr 2:165,601,007...165,629,415
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:100,551,307...100,559,447
Ensembl chr13:100,551,307...100,559,447
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:25,982,210...25,997,555
Ensembl chr18:25,984,638...25,997,555
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:30,779,149...30,781,297
Ensembl chr18:30,779,150...30,781,292
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:85,275,690...85,306,419
Ensembl chr16:85,275,678...85,306,366
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:82,415,599...82,419,918
Ensembl chr 9:82,415,605...82,419,288
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:88,047,186...88,088,477
Ensembl chr11:88,047,832...88,088,476
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:57,472,315...57,530,973
Ensembl chr 5:57,472,315...57,530,987
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:81,936,156...81,943,142
Ensembl chr10:81,936,444...81,942,188
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:84,330,064...84,595,296
Ensembl chr11:84,330,064...84,583,542
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions decreases expression |
ISO |
MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:98,668,231...98,689,471
Ensembl chr 9:98,668,231...98,684,900
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:27,835,346...27,919,285
Ensembl chr 6:27,887,797...27,915,563
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,552,550...119,577,796
Ensembl chr 3:119,561,290...119,577,806
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:100,829,593...100,840,498
Ensembl chr 9:100,829,552...100,840,504
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,936,721...3,995,740
Ensembl chr15:3,936,786...3,995,915
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:81,783,349...81,808,815
Ensembl chr 9:81,783,349...81,808,805
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:8,876,090...8,894,345
Ensembl chr 5:8,876,044...8,894,339
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:86,852,682...86,885,233
Ensembl chr11:86,852,711...86,885,224
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:88,498,271...88,533,730
Ensembl chr10:88,498,238...88,533,829
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:63,268,106...63,291,125
Ensembl chr X:63,268,037...63,292,092
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression multiple interactions |
EXP |
Heme results in increased expression of FABP2 mRNA [Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:149,984,206...149,988,744
Ensembl chr 4:149,984,206...149,988,295
|
|
G |
Gfod1 |
glucose-fructose oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:110,042,853...110,140,756
Ensembl chr 3:110,042,853...110,140,756
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:168,832,937...168,851,650
Ensembl chr 4:168,832,910...168,851,652
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,860,578...135,870,535
Ensembl chr 5:135,860,675...135,868,495
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:10,134,726...10,152,976
Ensembl chr17:10,137,974...10,152,956
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions increases degradation decreases abundance increases metabolic processing increases expression |
ISO EXP |
Heme results in decreased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] HMOX1 protein results in increased degradation of Heme HMOX1 protein results in decreased abundance of Heme HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:47,644,071...47,651,487
Ensembl chr13:47,644,071...47,647,715
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:89,919,570...89,929,774
Ensembl chr13:89,919,667...89,929,770
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:87,342,514...87,351,045
Ensembl chr10:87,342,619...87,351,045
|
|
G |
Lep |
leptin |
multiple interactions increases abundance |
ISO |
cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]; tin mesoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]] |
CTD |
PMID:23839791 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
LOC100364500 |
RT1 class I, locus CE11-like |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:2,704,153...2,707,111
Ensembl chr20:2,704,148...2,707,120
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
Heme analog results in increased secretion of LYZ protein SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:91,772,927...91,827,231
Ensembl chr13:91,773,004...91,776,397
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions decreases response to substance |
ISO |
[Heme co-treated with HPX protein] affects the activity of MT1 promoter MT1A protein results in decreased susceptibility to Heme |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:125,124,743...125,175,857
Ensembl chr 1:125,124,743...125,175,857
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein |
CTD |
PMID:23355332 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:126,254,090...126,259,204
Ensembl chr 5:126,254,142...126,259,200
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:137,618,891...137,923,385
Ensembl chr 3:137,618,898...137,925,605
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:167,309,021...167,335,550
Ensembl chr 1:167,309,051...167,334,741
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:111,998,204...112,048,847
Ensembl chr 9:111,998,203...112,027,240
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:91,451,890...91,500,675
Ensembl chr10:91,451,865...91,500,661
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:198,112,104...198,120,202
Ensembl chr 2:198,112,076...198,120,120
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:113,373,569...113,570,774
Ensembl chr13:113,373,578...113,571,648
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:11,253,424...11,271,873
Ensembl chr 3:11,254,026...11,271,872
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:140,822,141...140,835,244
Ensembl chr 5:140,822,141...140,834,959
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:74,173,809...74,291,188
Ensembl chr18:74,174,936...74,292,921
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:135,348,799...135,360,204
Ensembl chr X:135,348,436...135,360,203
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:20,435,098...20,439,206
Ensembl chr16:20,435,101...20,439,206
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:151,691,498...151,724,723
Ensembl chr 3:151,691,514...151,724,654
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:122,700,849...122,710,907
Ensembl chr 7:122,700,854...122,709,935
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Heme analog affects the localization of RELA protein |
CTD |
PMID:23355332 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:140,552,704...140,556,980
Ensembl chr 7:140,552,733...140,556,639
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:111,565,646...111,587,184
Ensembl chr 3:111,565,650...111,587,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:196,495,867...196,527,412
Ensembl chr 2:196,495,867...196,527,127
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:90,056,726...90,075,159
Ensembl chr13:90,058,127...90,075,144
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
|
|
G |
Smarcb1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:13,679,955...13,702,821
Ensembl chr20:13,680,716...13,704,931
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:165,600,934...165,629,415
Ensembl chr 2:165,601,007...165,629,415
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:100,551,307...100,559,447
Ensembl chr13:100,551,307...100,559,447
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:25,982,210...25,997,555
Ensembl chr18:25,984,638...25,997,555
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:30,779,149...30,781,297
Ensembl chr18:30,779,150...30,781,292
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:85,275,690...85,306,419
Ensembl chr16:85,275,678...85,306,366
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:82,415,599...82,419,918
Ensembl chr 9:82,415,605...82,419,288
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:88,047,186...88,088,477
Ensembl chr11:88,047,832...88,088,476
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:57,472,315...57,530,973
Ensembl chr 5:57,472,315...57,530,987
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:81,936,156...81,943,142
Ensembl chr10:81,936,444...81,942,188
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:84,330,064...84,595,296
Ensembl chr11:84,330,064...84,583,542
|
|
|
G |
Aco1 |
aconitase 1 |
decreases activity |
EXP |
Hemin results in decreased activity of ACO1 protein |
CTD |
PMID:16568477 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
increases expression |
EXP |
Hemin results in increased expression of ACO2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases secretion |
EXP |
Hemin results in increased secretion of ADIPOQ protein |
CTD |
PMID:20016031 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of ALAS2 mRNA [catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol promotes the reaction [Hemin results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of ALAS2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of ALAS2 mRNA] |
CTD |
PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Hemin binds to ALB protein |
CTD |
PMID:10506189 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein] |
CTD |
PMID:17541025 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
increases expression |
ISO |
Hemin results in increased expression of ARL6IP5 protein |
CTD |
PMID:16430862 |
|
NCBI chr 4:129,574,363...129,598,240
Ensembl chr 4:129,574,264...129,598,915
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
Hemin results in decreased localization of and results in decreased activity of BACH1 protein |
CTD |
PMID:18550526 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Hemin promotes the reaction [Cisplatin results in increased expression of BAX protein] Hemin results in increased expression of BAX protein |
CTD |
PMID:27815112 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Hemin results in decreased expression of BCL2 protein |
CTD |
PMID:27815112 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
Hemin results in increased expression of BIRC2 protein |
CTD |
PMID:14647439 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in increased cleavage of CASP3 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form Hemin results in increased cleavage of CASP3 protein Hemin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:17173083 PMID:18845130 PMID:19150641 PMID:19520142 PMID:26747958 PMID:27815112 PMID:31054940 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein] Hemin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:19150641 PMID:27815112 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of CDH1 mRNA |
CTD |
PMID:29269057 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein] |
CTD |
PMID:14647439 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases degradation |
ISO |
Hemin results in decreased degradation of CDKN1B protein |
CTD |
PMID:17283133 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA] |
CTD |
PMID:29749404 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]; [Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [thiamet G results in increased O-linked glycosylation of CHD4 protein]; [Hemin co-treated with hexamethylene bisacetamide] results in decreased O-linked glycosylation of CHD4 protein |
CTD |
PMID:27231347 |
|
NCBI chr 4:157,612,531...157,645,660
Ensembl chr 4:157,612,536...157,645,659
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Crh |
corticotropin releasing hormone |
increases secretion multiple interactions |
ISO |
Hemin results in increased secretion of CRH protein mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein] |
CTD |
PMID:11232018 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 mRNA]; Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 protein]] |
CTD |
PMID:23272707 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [Mercuric Chloride inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [sodium arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]] |
CTD |
PMID:20188822 PMID:20837117 PMID:22120038 PMID:22159698 PMID:26747958 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP1A2 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]] |
CTD |
PMID:22159698 PMID:26747958 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of CYP2A5 mRNA; Hemin results in increased expression of CYP2A5 protein [tin protoporphyrin IX co-treated with Hemin] affects the localization of CYP2A5 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of CYP2A5 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of CYP2A5 mRNA; NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:22859313 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP2B1 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP2B1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP2B1 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]] |
CTD |
PMID:11368792 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] Hemin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] Hemin results in increased expression of DDIT3 mRNA |
CTD |
PMID:26747958 PMID:29749404 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of EFNA1 mRNA |
CTD |
PMID:32198055 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [Hemin results in increased expression of FOS mRNA]; KN 62 inhibits the reaction [Hemin results in increased expression of FOS mRNA]; staurosporine aglycone inhibits the reaction [Hemin results in increased expression of FOS mRNA] |
CTD |
PMID:10381381 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
decreases expression |
ISO |
Hemin results in decreased expression of FOSL1 protein |
CTD |
PMID:20006635 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
EXP ISO |
Hemin results in increased expression of FTH1 mRNA; Hemin results in increased expression of FTH1 protein |
CTD |
PMID:15893546 PMID:16568477 PMID:17469137 PMID:29749404 PMID:31054940 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO EXP |
[Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA Hemin results in increased expression of FTL1 mRNA Hemin results in increased expression of FTL mRNA; Hemin results in increased expression of FTL1 protein |
CTD |
PMID:12393473 PMID:15893546 PMID:16568477 PMID:29749404 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gata1 |
GATA binding protein 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GATA1 mRNA catechol promotes the reaction [Hemin results in increased expression of GATA1 mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Hemin promotes the reaction [catechol results in increased expression of GATA1 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:28552822 |
|
NCBI chr X:15,273,937...15,281,759
Ensembl chr X:15,378,789...15,382,066
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression multiple interactions |
ISO |
Hemin results in decreased expression of GATA2 mRNA hydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of GATA2 mRNA] |
CTD |
PMID:21414390 |
|
NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Hemin results in increased expression of GCLC mRNA |
CTD |
PMID:16631525 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Hemin results in increased stability of and results in increased expression of GSTP1 mRNA |
CTD |
PMID:15313425 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
decreases activity |
ISO |
Hemin results in decreased activity of GSTZ1 protein |
CTD |
PMID:1846734 |
|
NCBI chr 6:111,176,798...111,187,246
Ensembl chr 6:111,176,798...111,187,244
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression multiple interactions decreases response to substance |
ISO |
Hemin results in increased expression of HAMP mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA; [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]; necrostatin-1 promotes the reaction [HAMP mRNA results in decreased susceptibility to Hemin] |
CTD |
PMID:29749404 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol promotes the reaction [Hemin results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HBB mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]; trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 PMID:30327826 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA Hemin results in decreased expression of HIF1A mRNA |
CTD |
PMID:12393473 PMID:29749404 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol promotes the reaction [Hemin results in increased expression of HMBS mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HMBS mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression decreases expression increases activity decreases response to substance |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased activity of HMOX1 protein] which results in decreased chemical synthesis of Reactive Oxygen Species; [Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Genistein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Curcumin results in increased expression of HMOX1 mRNA]; herbimycin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] Hemin results in increased expression of HMOX1 mRNA; Hemin results in increased expression of HMOX1 protein Hemin results in decreased expression of HMOX1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; [Hemin co-treated with Fructose] results in increased expression of HMOX1 protein; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein; [Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein]; chromium mesoporphyrin inhibits the reaction [[Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Hemin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [3-hydroxyflavone results in increased expression of HMOX1 protein]; Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; Hemin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Quercetin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Hemin |
CTD |
PMID:3343248 PMID:8764571 PMID:9337616 PMID:9722676 PMID:10349844 PMID:10473555 PMID:11232018 PMID:12051994 PMID:12393473 PMID:12690112 PMID:14563492 PMID:14647439 PMID:14871405 PMID:15316927 PMID:15589375 PMID:16109301 PMID:16462769 PMID:16631525 PMID:16647178 PMID:16839318 PMID:16959797 PMID:17173083 PMID:17204476 PMID:17275847 PMID:17420286 PMID:17464175 PMID:17541025 PMID:17979934 PMID:18206168 PMID:18215737 PMID:18357586 PMID:18550526 PMID:18845130 PMID:19080378 PMID:19136476 PMID:19190261 PMID:19520142 PMID:20016031 PMID:20638379 PMID:20961405 PMID:21525764 PMID:22859313 PMID:23272707 PMID:23942037 PMID:24095726 PMID:25268984 PMID:25449124 PMID:25824035 PMID:26747958 PMID:27777014 PMID:27815112 PMID:27830717 PMID:29086419 PMID:29749404 PMID:30040983 PMID:31054940 PMID:32671443 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases response to substance |
ISO |
HMOX2 protein results in decreased susceptibility to Hemin |
CTD |
PMID:15589375 PMID:16459095 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA |
CTD |
PMID:12393473 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10349844 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il18 |
interleukin 18 |
multiple interactions decreases response to substance |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]; Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of IL6 mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA |
CTD |
PMID:29749404 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Fructose results in increased expression of INS protein] |
CTD |
PMID:25268984 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions |
EXP |
Hemin results in decreased expression of and results in decreased activity of IREB2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
Hemin results in decreased expression of IVL mRNA |
CTD |
PMID:20006635 |
|
NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
ISO EXP |
[Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Hemin results in decreased expression of JUN mRNA Hemin promotes the reaction [Paraquat results in increased phosphorylation of JUN protein] |
CTD |
PMID:12393473 PMID:19080378 PMID:20016031 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
ISO |
Hemin results in decreased expression of KEAP1 protein |
CTD |
PMID:27777014 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 mRNA; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 4:125,684,816...126,300,013
Ensembl chr 4:125,687,307...125,958,112
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Hemin results in increased phosphorylation of MAPK1 protein diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16959797 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 7:130,121,678...130,129,199
Ensembl chr 7:130,121,687...130,128,604
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein] |
CTD |
PMID:18215737 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16959797 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Hemin promotes the reaction [Paraquat results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19080378 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA] Hemin results in decreased expression of MAPK9 mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]] |
CTD |
PMID:27830717 |
|
NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Gallic Acid results in increased activity of MGST1 protein] |
CTD |
PMID:19111564 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mir486 |
microRNA 486 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of MIR486-1 mRNA [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of MIR486-1 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
Ensembl chr16:73,680,363...73,680,490
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Hemin results in increased expression of MMP1 protein |
CTD |
PMID:19136476 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:17979934 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA |
CTD |
PMID:12393473 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA |
CTD |
PMID:12393473 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NFE2 mRNA catechol promotes the reaction [Hemin results in increased expression of NFE2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of NFE2 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of NFE2 mRNA] |
CTD |
PMID:21414390 PMID:28552822 |
|
NCBI chr 7:144,872,739...144,880,092
Ensembl chr 7:144,872,747...144,880,092
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases expression affects localization decreases expression |
ISO EXP |
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; diacetyldichlorofluorescein inhibits the reaction [Hemin affects the localization of NFE2L2 protein]; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Hemin] affects the localization of NFE2L2 protein; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10473555 PMID:16959797 PMID:21464371 PMID:21525764 PMID:22859313 PMID:23272707 PMID:25824035 PMID:26747958 PMID:27777014 PMID:31054940 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; Hemin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [3-hydroxyflavone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein] |
CTD |
PMID:14563492 PMID:15316927 PMID:26747958 PMID:27815112 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Nitroglycerin co-treated with Hemin] results in increased expression of NOS3 mRNA |
CTD |
PMID:17541025 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NQO1 mRNA; Hemin results in increased expression of NQO1 protein Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:21464371 PMID:31054940 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of NRF1 protein] |
CTD |
PMID:30040983 |
|
NCBI chr 4:57,335,732...57,445,317
Ensembl chr 4:57,378,069...57,445,341
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein] |
CTD |
PMID:27231347 |
|
NCBI chr X:71,540,870...71,585,906
Ensembl chr X:71,528,988...71,585,908
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases expression |
EXP |
Hemin results in decreased expression of PDE5A protein |
CTD |
PMID:16839318 |
|
NCBI chr 2:226,899,604...227,044,916
Ensembl chr 2:226,900,619...227,041,576
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein |
CTD |
PMID:20961405 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of PDGFRB mRNA |
CTD |
PMID:32198055 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases activity |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Dimethyl Sulfoxide promotes the reaction [Hemin results in decreased activity of POR protein]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin promotes the reaction [Dimethyl Sulfoxide results in decreased activity of POR protein] |
CTD |
PMID:11368792 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of PPARGC1A protein] |
CTD |
PMID:30040983 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
increases response to substance |
ISO |
PTGER2 gene mutant form results in increased susceptibility to Hemin |
CTD |
PMID:25451967 |
|
NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAP1A protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:177,836,191...178,057,378
Ensembl chr 2:177,836,202...178,057,157
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr13:47,956,754...48,022,333
Ensembl chr13:47,956,790...48,022,333
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] Hemin results in decreased expression of RELA mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression affects response to substance |
ISO |
[SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form [Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; Acetylcysteine inhibits the reaction [Hemin results in increased expression of SESN2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:31054940 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]]; Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19190261 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Hemin promotes the reaction [Acetaminophen results in increased expression of SOD2 protein] |
CTD |
PMID:12051994 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tfap2c |
transcription factor AP-2 gamma |
decreases expression |
EXP |
Hemin results in decreased expression of TFAP2C mRNA |
CTD |
PMID:20016031 |
|
NCBI chr 3:170,550,314...170,558,197
Ensembl chr 3:170,550,314...170,558,194
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
EXP ISO |
Hemin results in decreased expression of TFRC protein Hemin results in decreased expression of TFRC mRNA; Hemin results in decreased expression of TFRC protein [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; hydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of TFRC mRNA] |
CTD |
PMID:12393473 PMID:16568477 PMID:16760464 PMID:21414390 PMID:25576684 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[Hemin co-treated with Tretinoin] affects the localization of TGM2 protein |
CTD |
PMID:15556610 |
|
NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of TNF mRNA; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] Hemin inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:17173083 PMID:19150641 PMID:26747958 PMID:27815112 PMID:29269057 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased phosphorylation of VASP protein] |
CTD |
PMID:17541025 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
G |
Zfp36 |
zinc finger protein 36 |
multiple interactions increases expression |
ISO |
zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA] |
CTD |
PMID:24095726 |
|
NCBI chr 1:85,380,088...85,382,565
Ensembl chr 1:85,380,088...85,382,569
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
sapropterin inhibits the reaction [Fructose results in decreased expression of ADIPOQ mRNA]; sapropterin inhibits the reaction [Fructose results in decreased expression of ADIPOQ protein] |
CTD |
PMID:17098227 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
APP gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin; GW 501516 inhibits the reaction [APP gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin] |
CTD |
PMID:22886847 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
sapropterin inhibits the reaction [Methotrexate results in increased expression of CDKN1A protein] |
CTD |
PMID:22183962 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Epo |
erythropoietin |
multiple interactions increases abundance |
ISO |
EPO protein inhibits the reaction [GCH1 mutant form results in decreased abundance of sapropterin] EPO protein results in increased abundance of sapropterin EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7,8-dihydrobiopterin]; EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides]; EPO protein inhibits the reaction [HPH1 gene mutant form results in increased oxidation of sapropterin] |
CTD |
PMID:25041251 PMID:25490417 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
decreases abundance affects abundance multiple interactions increases chemical synthesis |
ISO |
GCH1 mutant form results in decreased abundance of sapropterin GCH1 protein affects the abundance of sapropterin [GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7,8-dihydrobiopterin; [Resveratrol results in increased expression of GCH1 mRNA] which results in increased abundance of sapropterin; EPO protein inhibits the reaction [[GCH1 gene mutant form results in increased oxidation of sapropterin] which results in increased chemical synthesis of 7,8-dihydrobiopterin]; GCH1 gene mutant form results in increased oxidation of and results in decreased abundance of sapropterin GCH1 protein results in increased chemical synthesis of sapropterin EPO protein inhibits the reaction [GCH1 mutant form results in decreased abundance of sapropterin] |
CTD |
PMID:14551046 PMID:20610621 PMID:21963838 PMID:25041251 PMID:25490417 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases activity multiple interactions |
ISO |
sapropterin results in increased activity of NOS3 protein sapropterin deficiency inhibits the reaction [NOS3 protein results in increased abundance of Superoxides]; sapropterin deficiency promotes the reaction [NOS3 protein results in increased abundance of Superoxides] [NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides; EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides] |
CTD |
PMID:19011239 PMID:23753407 PMID:25490417 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Sct |
secretin |
increases abundance |
ISO |
SCT protein results in increased abundance of sapropterin |
CTD |
PMID:16168596 |
|
NCBI chr 1:214,264,865...214,277,437
Ensembl chr 1:214,264,754...214,265,668
|
|
G |
Snca |
synuclein alpha |
increases abundance |
ISO |
SNCA mutant form results in increased abundance of sapropterin |
CTD |
PMID:24148766 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
sapropterin inhibits the reaction [Methotrexate results in increased expression of TP53 protein] |
CTD |
PMID:22183962 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|